Answers are grounded in this paper and cite their sources.
The review showed lower recurrence rate, longer recurrence-free survival and overall survival and lower recurrence-related mortality in sirolimus-treated patients in comparison with the calcineurin inhibitor-treated patients following liver transplantation for hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Menon et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: